Cytotoxicity, apoptosis and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation

Cancer Gene Therapy

Volumn 7, Issue 7, 2000, Pages 1051-1059

  Spear, Matthew A ^a,d   Sun, Fang ^a,b   Eling, David J ^a   Gilpin, Elizabeth ^a   Kipps, Thomas J ^a   Chiocca, E Antonio ^c   Bouvet, Michael ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UCSD MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Glioma; Herpes simplex virus type 1; Ionizing radiation; Pancreatic cancer; Ribonucleotide reductase

Indexed keywords

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTER; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; INCUBATION TIME; IONIZING RADIATION; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; UTERINE CERVIX CARCINOMA; VIRUS LOAD; VIRUS REPLICATION;

HERPES; HUMAN HERPESVIRUS 1; MAMMALIA;

EID: 0033943687     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700208     Document Type: Article

References (24)

1. Kim JH, Kolozsvary A, Rogulski K, Khil MS, Brown SL, Freytag SO. Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene. Cancer J Sci Am. 1998;4:364-369.
2. Gabel M, Kim JH, Kolozsvary A, Khil M, Freytag S. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene. Int J Radiat Oncol Biol Phys. 1998;41:883-887.
3. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994;54: 5745-5751.
4. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54:3963-3966.
5. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis isolation and characterization of an Icp6 Lac-Z insertion mutant. J Virol. 1988;62:196-205.
6. Goldstein DJ, Weller SK. Factors present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology. 1988;166:41-51.
7. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Influence of p53 status on the efficacy of HSV-mediated cancer gene therapy. Gastroenterology. 1998;114:A1435.
8. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998;16: 444-448.
9. Advani SJ, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 1998;5: 160-165.
10. Kuo M-L, Kinsella TJ. Expression of ribonuclease reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res. 1998;58:2245-2252.
11. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
12. 6(3), acts as a mitochondrial probe in human neutrophils. Biochem Biophys Res Commun. 1982;108:1495-1501.
13. Hu D, Kipps T. Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. Cell Immunol. 1999;195:43-52.
14. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
15. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA. 1995; 92:1411-1415.
16. Andreansky SS, He B, Gillespie GY, et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA. 1996:11313-11318.
17. Berk DA, Yuan F, Leunig M, Jain RK. Interstitial diffusion and convection of macromolecules in a human tumor xenograft. FASEB J. 1993;7:A241.
18. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 1997;4:1-23.
19. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM. Activation of the CD95 (APO-1/Fas) pathway in drug-and γ-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. 1998;5:884-893.
20. Hertveldt K, Philippe J, Thierens H, Cornelissen M, Vral A, De Ridder L. Flow cytometry as a quantitative and sensitive method to evaluate low dose radiation induced apoptosis in vitro in human peripheral blood lymphocytes. Int J Radiat Biol. 1997;71:429-433.
21. Galvan V, Roizman B. Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc Natl Acad Sci USA. 1998;95: 3931-3936.
22. Leopardi R, Van Sant C, Roizman B. The herpes simplex virus 1 protein kinase U-S3 is required for protection from apoptosis induced by the virus. Proc Natl Acad Sci USA. 1997;94:7891-7896.
23. Tanaka N, Sato M, Lamphier MS, et al. Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells. 1998;3:29-37.
24. Kim J, Kim SH, Kolozsvary A, Brown SL, Kim OB, Freytag SO. Selective enhancement of radiation response of herpes simplex virus thymidine kinase-transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys. 1995;33: 861-868.